Gastroesophageal reflux disease (GERD) is prevalent globally and represents one of the most common
gastrointestinal diseases. The term GERD covers a spectrum of conditions including non-erosive
gastroesophageal reflux disease. (NERD) This condition is defined as at least weekly heartburn and/or
regurgitation. Vonprazan is in a new class of acid-inhibitory agents called potassium competitive
blockers. Recent studies have shown a rapid onset of action after the first dose providing relief.
What we need:
The subject is ≥18 years of age at the time of informed consent signing
The subject identified their main symptom as heartburn, a burning sensation in the retrosternal
area (behind the breastbone)
History of episodes of heartburn for 6 months or longer prior to screening
Heartburn reported on 4 or more days during any 7 consecutive days in the Screening Period as
recorded in the electronic diary
What we cannot have:
The subject has irritable bowel syndrome (IBS)
The subject has endoscopic Barrett’s esophagus (>1 cm of columnar-lined esophagus) and/or
definite dysplastic changes in the esophagus
The subject has a history of surgery or endoscopic treatment affecting gastroesophageal reflux,
including fundoplication and dilation for esophageal stricture (except Schatzki’s ring) or a history
of gastric or duodenal surgery (except endoscopic removal of benign polyps)
The subject has any other condition affecting the esophagus (Ask to view the full list of
conditions) 
